P44 42 mapk sirna

Manufactured by Cell Signaling Technology

The P44/42 MAPK siRNA is a targeted small interfering RNA (siRNA) designed to specifically silence the expression of the p44/42 mitogen-activated protein kinase (MAPK) gene. The p44/42 MAPK, also known as ERK1/2, is a key regulator of cellular processes such as proliferation, differentiation, and survival. This siRNA provides a tool for researchers to investigate the functional role of p44/42 MAPK in their experimental systems.

Automatically generated - may contain errors

Lab products found in correlation

Antihuman erα hc 20 antibody sc 543, by Santa Cruz Biotechnology (2 mentions) Fulvestrant, by Merck Group (2 mentions) Mk 2206, by Selleck Chemicals (2 mentions) P her2 tyr1248, by Cell Signaling Technology (1 mentions) P mapk, by Cell Signaling Technology (1 mentions) Antihuman her2 antibody, by Abcam (1 mentions) Sirna sc 37007, by Santa Cruz Biotechnology (1 mentions)

Close spelling variants of this product

P44/42 MAPK (90 citations) SignalSilence® p44/42 MAPK (Erk1/2) siRNA (5 citations) SiRNAs (4 citations) P44/42 MAPK (ERK1/2) siRNA (2 citations)

2 protocols using p44 42 mapk sirna

Investigating PDCD4, PTEN, and HER2 Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antihuman PDCD4 (#9535), PTEN (#9188), p-HER2 (Tyr1248) (#2247), p-MAPK (#9101), MAPK (#9102), p-AKT (Ser473) (#9271), AKT (#9272), GAPDH (#2118) antibodies were obtained from Cell Signaling Technology. Antihuman HER2 antibody (#06–562) was from Abcam Inc. Antihuman ERα (HC-20) antibody (sc-543) was from Santa Cruz Biotechnology. The p44/42 MAPK siRNA (#6560) was obtained from Cell Signaling Technology. The nontargeting control siRNA (sc-37007) was from Santa Cruz Biotechnology. The AKT inhibitor MK-2206 was obtained from Selleck Chemicals. The ER antagonist fulvestrant was from Sigma-Aldrich. The anti-miR-21 inhibitor and inhibitor negative control were purchased from Ambion.

Chen Z., Yuan Y.C., Wang Y., Liu Z., Chan H.J, & Chen S. (2015). Down-regulation of program cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer. Breast cancer research and treatment, 152(1), 29-39.

+ Open protocol

+ Expand

Signaling Pathway Profiling Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antihuman MYC (#5605), p-MAPK (#9101), MAPK (#9102), p-AKT (Ser473) (#9271), AKT (#9272), p-ER (Ser167) (#5587), GAPDH (#2118) antibodies were obtained from Cell Signaling Technology. Antihuman HER2 (#06-562) and p-ERα (Ser118) (ab32396) antibodies were from Abcam Inc. Antihuman ERα (HC-20) antibody (sc-543) was from Santa Cruz Biotechnology. The ER antagonist fulvestrant (#14409) and the SLC1A5 inhibitor L-Glutamic acid γ-(p-nitroanilide) (GPNA) (G6133) were obtained from Sigma-Aldrich. The glutaminase inhibitor compound 968 (#352010) was from EMD Millipore. The AKT inhibitor MK-2206 (S1078) was from Selleck Chemicals. The nontargeting control siRNA (sc-37007) and MYC siRNA (sc-29226) were obtained from Santa Cruz Biotechnology. The HER2 siRNA (L-003126-00) was from Dharmacon. The p44/42 MAPK siRNA (#6560) was from Cell Signaling Technology.

Chen Z., Wang Y., Warden C, & Chen S. (2015). Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells. The Journal of steroid biochemistry and molecular biology, 149, 118-127.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!